Quang Pham Sells Shares of CVKD
Quang Pham, Chairman and CEO of CVKD, sold 3,666 shares on June 15, 2026.
Key Points
- Quang Pham, Chairman and CEO of CVKD, sold 3,666 shares for $13,124.28 on June 15, 2026.
- CVKD shares traded near $3.33 with insider sales occurring at prices up to $4.38.
- Vanguard Capital Management added 45,201 shares, while BlackRock increased its stake by 1,974 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Quang Pham, the Chairman, CEO, and Interim CFO of CVKD, sold 3,666 shares of the company on June 15, 2026. The shares were sold at an average price of $3.58, totaling $13,124.28. This transaction was not part of a pre-planned trading program.
Other Institutional Activity in CVKD
Vanguard Capital Management LLC significantly increased its position in CVKD, adding 45,201 shares to hold a total of 45,201 shares valued at approximately $231,429. Geode Capital Management, LLC also boosted its holdings by 7,098 shares, reaching a total of 21,626 shares worth about $110,724. Vanguard Fiduciary Trust Co acquired 8,311 shares, bringing its total to 8,311 shares valued at $42,552. Meanwhile, BlackRock, Inc. increased its stake by 1,974 shares to 5,496 shares, valued at $28,140.
Cadrenal Therapeutics, Inc. Stock Up 116.2%
Shares of CVKD traded around $3.33 recently. The stock has experienced insider sales at varied prices, with some transactions occurring at prices as high as $4.38 per share.
$CVKD stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Cadrenal Therapeutics, Inc.
Quang Pham has been actively selling shares of CVKD. Apart from the June 15 transaction, he sold 12,996 shares on June 12 at $3.94 each, and 1,462 shares on June 11 at $4.12 each. Earlier, on June 10, he sold 3,500 shares at $4.21, part of a planned sale. On June 9 and June 8, he sold 12,992 and 5,893 shares at $4.06 and $4.38, respectively, both under planned sales.
Analysts Set New Price Targets
On April 7, 2026, HC Wainwright & Co. maintained a 'buy' rating on CVKD with a $13.00 price target. This follows a series of 'buy' ratings by the firm, including a reiterated target of $32.00 in May 2025. Noble Financial also maintained a 'buy' rating with a $4.00 target on March 13, 2024.
Bottom Line
Quang Pham's recent sales of CVKD shares offer insight into insider activity at the company. Investors might keep an eye on these insider transactions for potential implications. Institutional interest in CVKD remains strong, with notable increases from several major funds. Analyst ratings continue to reflect a positive outlook, though it's important to remember that these reports are retrospective and may not reflect current positions.
Get Cadrenal Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CVKD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.